Background -Salmeterol and formoterol have a lower intrinsic activity at P2 receptors than isoprenaline in human bronchus in vitro. The aim of the present study was to evaluate in vivo the P2 agonistlantagonist activity of salmeterol and formoterol at rest with low endogenous adrenergic tone, on exercise with raised endogenous adrenergic tone, and in the presence of fenoterol, an exogenous full P2 receptor agonist. Methods -Eight normal subjects were randomised to receive single doses ofplacebo, salmeterol 300 sg, formoterol 72 pg, or propranolol 80 mg at weekly intervals. P2 adrenoceptor responses were evaluated at rest, at peak exercise, and after treatment with fenoterol 2 4 mg. Results -At rest salmeterol and formoterol exhibited equivalent P2 agonist activity with regard to decrease in serum potassium levels and increase in finger tremor, with propranolol having no effect. Salmeterol and formoterol, like propranolol, potentiated the hyperkalaemic delta response to exercise compared with placebo, consistent with P2 antagonism: (mean difference and 95% confidence interval (CI) compared with placebo) salmeterol 0-20 (0.02 to 0.38) mmol/l, formoterol 0-17 (0.00 to 0.34) mmol/l, propranolol 0 45 (0.08 to 0.82) mmol/l. Propranolol blunted the heart rate delta response to exercise, consistent with P, blockade, whilst salmeterol and formoterol had no effect. Salmeterol and formoterol are potent long acting 2 receptor agonists. The potency of these drugs will determine the dose required to produce a given effect, but it is important to appreciate that factors other than potency may influence the expression of their 12 agonist activity. Both salmeterol and formoterol have a lower intrinsic activity than isoprenaline in human bronchus in vitro, and therefore at saturating concentrations will produce a lower maximal response, with salmeterol having a lower efficacy than formoterol.' In other words, they are less efficient than a full agonist at activating the receptor transduction mechanism required to produce a maximal cellular response. 
(-1.26 to -0.12) log units, formoterol -0-71 (-1.53 to 0.11) log units, propranolol -0 85 (-166 to -0.04) log units; heart rate, salmeterol -6 (-13 to 1) beats/ min, formoterol -10 (-19 to -1) beats/ min, propranolol -18 (-29 to -7) beats/ min.
Conclusions -At rest with low endogenous adrenergic tone salmeterol and formoterol showed equivalent P2 mediated agonist activity in terms of serum potassium and finger tremor responses. In the presence of raised endogenous adrenergic tone at peak exercise and in the presence of fenoterol (an exogenous full P2 receptor agon- Salmeterol and formoterol are potent long acting 2 receptor agonists. The potency of these drugs will determine the dose required to produce a given effect, but it is important to appreciate that factors other than potency may influence the expression of their 12 agonist activity. Both salmeterol and formoterol have a lower intrinsic activity than isoprenaline in human bronchus in vitro, and therefore at saturating concentrations will produce a lower maximal response, with salmeterol having a lower efficacy than formoterol.' In other words, they are less efficient than a full agonist at activating the receptor transduction mechanism required to produce a maximal cellular response. Finger tremor data were transformed using logarithm to base 10 to achieve conformation to a normal distribution prior to analysis. Data were then analysed using the Statgraphics software package (STSC Software, Rockville, USA). Effects at rest and in response to exercise and fenoterol were all analysed as delta responses -that is, the difference between the response before and after drug administration (tl-t0), before and after exercise (t2-tl), and before and after fenoterol (t4-t3). Comparisons were made by multifactorial analysis ofvariance (MANOVA) using subjects, treatments, and time as within factors for the analysis. Where the overall MANOVA was significant, Duncan's multiple range testing was used to establish where differences between treatments were significant. Differences from placebo, where significant, were calculated as means and 95% confidence intervals. A probability value of p<005 (two tailed) was considered significant for all tests.
Results

SUPINE REST
There were no significant differences in baseline (to) measurements between each ofthe four study days for any of the measured parameters.
One hour after dosing (t,) salmeterol and formoterol significantly (p<0 05) lowered serum potassium levels (as delta response, ti-to) compared with placebo, an effect consistent with 12 agonism: (mean differences and 95% CI versus placebo) salmeterol -038 (-0-65 to -0 11) mmol/l, formoterol -0-36 (-0-63 to-0 -09) mmol/l. Likewise, the finger tremor delta response was significantly (p<005) greater with salmeterol and formoterol than with placebo: salmeterol 0-56 (-0-16 and formoterol had no effect on this response. Propranolol significantly (p<0 05) potentiated the rise in potassium on exercise (t2-tI) consistent with 2 antagonism. Salmeterol and formoterol, like propranolol, also potentiated the potassium response to exercise compared with placebo: salmeterol 02 (0-02 to 0-38) mmol/ 1, formoterol 0-17 (0 0 to 0 34) mmol/l, propranolol 0 45 (0-08 to 0 82) mmol/l. Propranolol produced significantly greater potentiation of the delta potassium response than either salmeterol or formoterol. The absolute post exercise potassium level (t2) was significantly higher (p<0 05) with propranolol than with placebo, but salmeterol and formoterol were not significantly different from placebo (table) .
RESPONSES TO FENOTEROL
Propranolol significantly (p<005) attenuated the potassium, heart rate, and tremor response to fenoterol (t4-t3) compared with placebo, consistent with P2 antagonism: potassium 0-80 (0 54 to 1-06) mmol/l, heart rate -18 (-29 to -7) beats/min, tremor -0-85 (-1-66 to -0 04) log units (fig 2) . Salmeterol and formoterol also significantly (p<005) attenuated the hypokalaemic and tremor response to fenoterol compared with placebo: potassium: salmeterol 0-18 (0-0 to 0536) mmol/l, formoterol 0-17 (-0 03 to 0537) mmol/l; tremor: salmeterol -0-69 (-1-26 to -0 12) log units, formoterol -0-71 (-0 53 to 0 11) log units. In addition, formoterol also significantly (p<005) attenuated the heart rate response to fenoterol compared with placebo, with salmeterol showing a similar trend (p=0 = 06): formoterol -10 (-19 to -1) beats/min, salmeterol -6 (-13 to -1) beats/min. Propranolol produced significantly greater blunting of fenoterol induced delta heart rate and delta potassium responses (but not tremor responses) than either salmeterol or formoterol. There were no significant differences in the absolute values for serum potassium, finger tremor, or heart rate after fenoterol following treatment with salmeterol or formoterol compared with placebo.
The absolute values for heart rate and finger tremor after fenoterol were significantly lower (p<005) after treatment with propranolol than u.uII '7 1 In vitro studies with guinea pig airway have also shown that salmeterol can inhibit fenoterol and, to a lesser degree, salbutamol-induced relaxation. 4 In the present study we were unable to distinguish between the relative partial agonist activities of formoterol and salmeterol as they both produced comparable degrees of 132 agonism at rest and comparable 12 blockade with exercise and fenoterol responses. However, it was clearly evident that the P2 blockade of formoterol and salmeterol was less than that of propranolol. It may, however, be possible to make such a distinction between salmeterol and formoterol if dose ranging studies were performed using lower doses of partial agonist.
This study was confined to evaluating extrapulmonary 12 responses in normal individuals, and the clinical relevance in terms of modulation of bronchodilator response therefore remains unclear. Clearly salmeterol, a drug with relatively low efficacy, normally produces clinically significant degrees of bronchodilation. It is, however, worth noting that, in vitro, differences in intrinsic activity between agonists in terms of bronchodilator activity become more pronounced when bronchial tone is increased' as might occur in the setting of acute asthma. This may be compounded by the presence of raised endogenous adrenergic tone which might also result in the expression of antagonist effects by partial agonists such as salmeterol. Furthermore, it is possible that a P2 agonist with lower intrinsic activity such as salmeterol might result in a reduced bronchodilator response to an exogenous agonist with higher intrinsic activity such as salbutamol.
